On-Treatment Decline in Serum HBsAg Levels Predicts Sustained Immune Control and HBsAg Clearance 6 Months Post-Treatment in HBeAg-Positive Hepatitis B Virus-Infected Patients Treated with Peginterferon Alfa-2a [40KD] (PEGASYS)

发表时间：2010-05-13 标签： 壁报展示 其他肝病 壁报展示 相关搜索： HBsAg HBeAg-Positive Hepatitis B Virus-Infected PEGASYS